In contrast to Daniel et al. [44], Ramadan et al. have shown that either early or late low (20 mg/L) but not high doses (100 mg/L) of everolimus attenuated the loss of the slit diaphragm proteins nephrin and podocin in adriamycin-induced nephrotic syndrome (an experimental nephropathy that mimics minimal change disease), suggesting that the antiproteinuric effect of this agent at the therapeutic dose is due to preservation of nephrin and podocin. This evidence concerns the gene NPHS2 and lipoid nephrosis.